Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and m...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberto Esteban-Fernández, Alejandro Recio-Mayoral, Raquel López-Vilella, Gregorio de Lara, Moisés Barrantes-Castillo, Inés Gómez-Otero, Julio Nuñez-Villota, Carolina Robles-Gamboa, José López-Aguilera, Ángel Iniesta-Manjavacas, Paula Fluviá, Francisco Pastor-Pérez, Laia Belarte-Tornero, Gonzalo Alonso-Salinas, Pablo Díez-Villanueva
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
vericiguat
worsening heart failure
guideline-directed medical therapy
VERISEC registry
heart failure reduced ejection fraction
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full

Similar Items